These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 28983974)

  • 1. Molecular design of Stat3-derived peptide selectivity between BET proteins Brd2 and Brd4 in ovarian cancer.
    Zhu L; Ding X
    J Mol Recognit; 2018 Feb; 31(2):. PubMed ID: 28983974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct Roles of Brd2 and Brd4 in Potentiating the Transcriptional Program for Th17 Cell Differentiation.
    Cheung KL; Zhang F; Jaganathan A; Sharma R; Zhang Q; Konuma T; Shen T; Lee JY; Ren C; Chen CH; Lu G; Olson MR; Zhang W; Kaplan MH; Littman DR; Walsh MJ; Xiong H; Zeng L; Zhou MM
    Mol Cell; 2017 Mar; 65(6):1068-1080.e5. PubMed ID: 28262505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations.
    Wang Q; Li Y; Xu J; Wang Y; Leung EL; Liu L; Yao X
    Sci Rep; 2017 Aug; 7(1):8857. PubMed ID: 28821780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reshaping acetylated peptide selectivity between human BET Brd2 bromodomains BD-I and BD-II in glioblastoma by rationally grafting secondary anchor residues.
    Fei X; Wang A; Meng X; Wang Z
    Gen Physiol Biophys; 2018 Jul; 37(4):411-419. PubMed ID: 29956673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico design and molecular basis for the selectivity of Olinone toward the first over the second bromodomain of BRD4.
    Rodríguez Y; Gerona-Navarro G; Osman R; Zhou MM
    Proteins; 2020 Mar; 88(3):414-430. PubMed ID: 31587361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brd4-Brd2 isoform switching coordinates pluripotent exit and Smad2-dependent lineage specification.
    Fernandez-Alonso R; Davidson L; Hukelmann J; Zengerle M; Prescott AR; Lamond A; Ciulli A; Sapkota GP; Findlay GM
    EMBO Rep; 2017 Jul; 18(7):1108-1122. PubMed ID: 28588073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solution structure of the second bromodomain of Brd2 and its specific interaction with acetylated histone tails.
    Huang H; Zhang J; Shen W; Wang X; Wu J; Wu J; Shi Y
    BMC Struct Biol; 2007 Sep; 7():57. PubMed ID: 17848202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revealing binding selectivity of inhibitors toward bromodomain-containing proteins 2 and 4 using multiple short molecular dynamics simulations and free energy analyses.
    Wang LF; Wang Y; Yang ZY; Zhao J; Sun HB; Wu SL
    SAR QSAR Environ Res; 2020 May; 31(5):373-398. PubMed ID: 32496901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4- and BRD2/RING3-induced G1 cell cycle arrest.
    Ottinger M; Christalla T; Nathan K; Brinkmann MM; Viejo-Borbolla A; Schulz TF
    J Virol; 2006 Nov; 80(21):10772-86. PubMed ID: 16928766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis and binding properties of the second bromodomain of Brd4 with acetylated histone tails.
    Liu Y; Wang X; Zhang J; Huang H; Ding B; Wu J; Shi Y
    Biochemistry; 2008 Jun; 47(24):6403-17. PubMed ID: 18500820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NF-κB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells.
    Hishiki K; Akiyama M; Kanegae Y; Ozaki K; Ohta M; Tsuchitani E; Kaito K; Yamada H
    Leuk Res; 2018 Nov; 74():57-63. PubMed ID: 30300821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
    Dai X; Gan W; Li X; Wang S; Zhang W; Huang L; Liu S; Zhong Q; Guo J; Zhang J; Chen T; Shimizu K; Beca F; Blattner M; Vasudevan D; Buckley DL; Qi J; Buser L; Liu P; Inuzuka H; Beck AH; Wang L; Wild PJ; Garraway LA; Rubin MA; Barbieri CE; Wong KK; Muthuswamy SK; Huang J; Chen Y; Bradner JE; Wei W
    Nat Med; 2017 Sep; 23(9):1063-1071. PubMed ID: 28805820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1.
    Tumdam R; Kumar A; Subbarao N; Balaji BS
    SAR QSAR Environ Res; 2018 Dec; 29(12):975-996. PubMed ID: 30411639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
    Ran X; Zhao Y; Liu L; Bai L; Yang CY; Zhou B; Meagher JL; Chinnaswamy K; Stuckey JA; Wang S
    J Med Chem; 2015 Jun; 58(12):4927-39. PubMed ID: 26080064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of the Brd4 ET domain bound to a C-terminal motif from γ-retroviral integrases reveals a conserved mechanism of interaction.
    Crowe BL; Larue RC; Yuan C; Hess S; Kvaratskhelia M; Foster MP
    Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2086-91. PubMed ID: 26858406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors.
    Raj U; Kumar H; Varadwaj PK
    J Biomol Struct Dyn; 2017 Aug; 35(11):2351-2362. PubMed ID: 27494802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BET bromodomain proteins mediate downstream signaling events following growth factor stimulation in human lung fibroblasts and are involved in bleomycin-induced pulmonary fibrosis.
    Tang X; Peng R; Ren Y; Apparsundaram S; Deguzman J; Bauer CM; Hoffman AF; Hamilton S; Liang Z; Zeng H; Fuentes ME; Demartino JA; Kitson C; Stevenson CS; Budd DC
    Mol Pharmacol; 2013 Jan; 83(1):283-93. PubMed ID: 23115324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solution structures of two FHA1-phosphothreonine peptide complexes provide insight into the structural basis of the ligand specificity of FHA1 from yeast Rad53.
    Yuan C; Yongkiettrakul S; Byeon IJ; Zhou S; Tsai MD
    J Mol Biol; 2001 Nov; 314(3):563-75. PubMed ID: 11846567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoiesis provides a BRD's eye view of BET protein function.
    Stonestrom AJ; Hsu SC; Werner MT; Blobel GA
    Drug Discov Today Technol; 2016 Mar; 19():23-28. PubMed ID: 27769353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.